Search for: "Teva Branded Pharmaceutical Products R"
Results 61 - 80
of 92
Sorted by Relevance
|
Sort by Date
15 Mar 2008, 7:00 am
India: Gene silencing: (Spicy IP), India: US Patent reform implications for Indian Pharma: (Spicy IP), India: Generic pharmaceutical industry in the spotlight: (International Law Office), India: Supreme Court refuses to stay a Gujarat High Court decision restraining Ranbaxy from airing its controversial ads directed against Paras Pharma's 'Moov' brand: (Spicy IP),India: Patents on ARV drugs could increase costs: (Generic Pharmaceuticals & IP),US:… [read post]
8 Feb 2017, 3:09 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
2 Aug 2008, 12:54 am
: (Holman’s Biotech IP Blog), Daiichi’s open offer for 20% in Ranbaxy awaits Sebi nod: (GenericsWeb), Australia/India: Strides shows thumbs up for Indian generic industry acquiring controlling interest in Ascent: (Spicy IP), Europe: Significant date ahead for EU Paediatric Regulation: (SPC Blog), India: Grave diggers, ‘immoral’ patent and the National Biotech Regulatory Authority: (Spicy IP), UK: Monster trade mark infringement case: court reveals its thinking… [read post]
25 Jul 2008, 7:04 am
, (Daily Dose of IP), 26 August: WIPO symposium on IP and multilateral agreements – Geneva: (IPKat), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop –… [read post]
18 Jul 2008, 8:34 am
: (Patent Circle), Tanzania to conduct study on impact of counterfeit medicines: (Afro-IP), US: New rules on generic biological medicines under US Congressional debate: (Intellectual Property Watch), Pharma & Biotech - Products Acular (Ketorolac) – US: CAFC rules against Apotex reverse doctrine of equivalents: Roche Palo Alto & Allergan, Inc v Apotex: (Patent Circle), Carbatrol (Carbamazapine) – US: Federal judge allows Corepharma to seek DJ that its… [read post]
29 Feb 2008, 8:00 am
: (creativecommons.org)Pharma & BiotechPharma & Biotech - GeneralScience Commons news: A commons-sense approach to winning the drug discovery lottery: (creativecommons.org),India: Hindu Business Line reports on why pharma companies are pushing for tax incentives: (Spicy IP), India: J Mitra gets injunction against Span Diagnostics in patent dispute before Delhi High Court over device used in detection of Hep C: (Generic Pharmaceuticals & IP), India: Patent Office… [read post]
16 Jan 2017, 5:44 pm
Teva Pharmaceuticals USA, Inc., et al. [read post]
16 Aug 2008, 2:43 am
– discussion of Washington Post article on Ismed’s efforts to promote follow-on biologics approval pathway: (Patent Baristas), (Patent Docs), US: Congressional fact-finding on follow-on biologics: (Patent Docs), US: David v Monsanto: Biotechnology patent ‘exhaustion’ after Quanta, Supreme Court petition: (Hal Wegner), US: Ulysses Pharmaceuticals announces issuance of patent for novel class of ant [read post]
13 Jun 2008, 3:40 am
: (Patent Docs), Generic drug developers will continue to take advantage of global demand for lower-priced drugs, with Teva poised to maintain lead position says Goldman Sachs analyst: (GenericsWeb), Daiichi Sankyo takeover of Ranbaxy: (Profitability through Simplicity), (Spicy IP), (GenericsWeb), Canada: Generics to penetrate 26% pharma market in Canada says RNCOS research: (GenericsWeb), Canada: Generic drug makers spreading misinformation about patent regulation amendments to dodge real… [read post]
23 Aug 2008, 1:23 am
: (Part 1 - SPICY IP), (Part 2 - SPICY IP) Global – Copyright International Federation of the Phonographic Industry (IFPI): ‘Three strikes’ effort hit worldwide home run: (Ars Technica), How to attribute a Creative Commons licensed work: (Molly Kleinman), Chrysalis disappoints, as new artists fail to incubate: (IP finance), DRM for streaming music dies a quiet death: (Electronic Frontier Foundation), (Techdirt) Events 26 August:… [read post]
19 Sep 2008, 6:00 pm
: (Wired) The South strikes back against overreaching IP enforcement: (Intellectual Property Watch) WIPO assembly set to appoint new head: (Managing Intellectual Property) Open business systems fill gap in mainstream entertainment industry: (Intellectual Property Watch) Global - Trade Marks / Domain Names / Brands Brand values collapse in the face of global financial turmoil: (IAM), Genericness survey results: (Property, intangible) Reputation as risk: a lesson from the… [read post]
7 Mar 2008, 2:00 am
: (Techdirt) Global - Trade Marks / Domain Names / Brands UNCITRAL guidelines on IP securitization: the INTA’s response: (IP finance), Protection of geographical indications as part of WTO Doha Round negotiations? [read post]
4 Apr 2008, 1:00 am
: (IPBiz) Pharma & Biotech - Products Abilify (Aripiprazole) – Otsuka files US patent infringement suit against Teva over seeking approval for generic Abilify: (IP Law360), Aricept (Donepezil) – US federal judge grants Eisai’s request for preliminary injunction blocking Teva from marketing generic version of Aricept: (IP Law360), (Orange Book Blog), Carbatrol (Carbamazepine) – US federal judge delivers mixed… [read post]
28 Sep 2016, 8:39 am
Teva Pharmaceuticals USA, Inc., et al. [read post]
11 Jul 2008, 4:30 am
, (Daily Dose of IP), 11-12 September: US LSI: 4th annual conference on ‘Current issues in complex IP licensing’ – Philadelphia: (Patent Docs), 11 September/15 October: PLI seminar on developments in pharmaceutical and biotech patent law – New York/San Francisco: (Patent Docs), 15-16 September: UniForum & SAIIPL domain name ADR workshop – Centurion (South Africa): (Afro-IP), 15-16 September: US ACI 10th advanced forum on biotech… [read post]
5 Jul 2008, 11:05 am
: (Intellectual Property Watch), Why compulsory licenses are bad: a look at the sausage making process: (Techdirt) More on ACTA: (LawFont.com) Global - Trade Marks / Domain Names / Brands Brand Finance 500: the annual report on the world’s most valuable brands: (IP finance), Gretchen Olive’s ‘10 steps to an effective domain name policy’: (IPwar’s), ICANN approves GNSO proposals imposing financial penalty on registrars who… [read post]
29 Aug 2008, 1:25 pm
: (IP finance), Facebook removes international access to Scrabulous, except from India: (Ars Technica), (Techdirt), Reverse engineering can resolve conflict between standardisation and competition: (Techdirt), Benefits of piracy aren’t always in the expected places: (Techdirt) Events 1-3 September: Federation of Indian Chambers of Commerce and Industry, Department of Industrial Property and Promotion, and WIPO conference on ‘Development and IP: Building synergies… [read post]
1 Feb 2008, 12:00 am
: (IPBiz),State of the Union address 28 Jan 2008: statement regarding patenting human life: (IPBiz), (Patently-O),Alnylam Pharmaceuticals secures UK patent covering molecules that affect RNA interference: (SmartBrief),Doha style compulsory licences for exports: The politics…: (Spicy IP),Pushing to compulsory licensing: Pharma companies heading closer to Doha: (Spicy IP),Financial Express on the battle between big pharma companies and the… [read post]
2 May 2008, 7:00 am
: Lupin v Abbott Labs: (FDA Law Blog), Plavix (Clopidogrel) – US: Apotex sues FDA to recover 180-day exclusivity on generic Plavix: (Orange Book Blog), Plavix (Clopidogrel) – US: Former Bristol-Myers Squibb executive charged over lying about Plavix deal struck with rival Apotex: (Managing Intellectual Property), Risperdal (Resperidone) – US: Apotex files motion to intervene in relisting of Risperdal patent case; Teva quickly files opposition:… [read post]
20 Jun 2008, 8:07 am
: (Spicy IP), Latin America: Merck Serono signs distribution agreement with Bristol-Myers Squibb for portfolio of established pharmaceutical brands in Latin America: (IP tango), US: Biotech industry growth to slow due to funding pressures and competition from biosimilars: (Managing Intellectual Property), US: House Commerce Committee posts responses to its questions on biogenerics; not surprisingly, the views run the gamut: (FDA Law Blog), US: Biosimilar debate heats up at BIO:… [read post]
